Fixed or adjustable maintenance-dose budesonide/formoterol compared with fixed maintenance-dose salmeterolfluticasone propionate in asthma patients aged ≥16 years: Post hoc analysis of a randomized, double-blindopen-label extension, parallel-group study

Clinical Drug Investigation

Volumn 30, Issue 7, 2010, Pages 439-451

  Aalbers, René ^a  

^a MARTINI HOSPITAL   (Netherlands)

Author keywords

Asthma; Budesonideformoterol; Salmeterolfluticasone propionate; Therapeutic use; Treatment

Indexed keywords

ADOAIR; BUDESONIDE PLUS FORMOTEROL; FLUTICASONE PROPIONATE PLUS SALMETEROL; SALBUTAMOL; SERETIDE DISKUS; TERBUTALINE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHONIA; FEMALE; FORCED EXPIRATORY VOLUME; HOSPITALIZATION; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; RHINITIS; VIRUS INFECTION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953352380     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11533420-000000000-00000     Document Type: Article

References (40)

1. Partridge MR. Asthma: 1987-2007. What have we achieved and what are the persisting challenges? Prim Care Respir J 2007; 16 (3): 145-148
2. Desfougeres J-L, Sohier B, Freedman D, et al. Has asthma control improved since AIRE? Results of a survey in 5 European countries [abstract]. Eur Respir J 2007; 30: 249s
3. Price D, Horne R, Ryan D, et al. ABS74: Large variations in asthma control between UK general practices participating in the asthma control, concordance and tolerance (ACCT) Initiative [abstract]. Prim Care Respir J 2006; 15: 206
4. Sovani MP, Whale CI, Oborne J, et al. Poor adherence with inhaled corticosteroids for asthma: can using a single inhaler containing budesonide and formoterol help? Br J Gen Pract 2008; 58 (546): 37-43
5. Partridge MR, Van der Molen T, Myrseth SE, et al. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006; 6: 13
6. Rabe KF, Vermeire PA, Soriano JB, et al. Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. Eur Respir J 2000; 16 (5): 802-807
7. Haughney J, Barnes G, Partridge M, et al. The Living & Breathing Study: a study of patients' views of asthma and its treatment. Prim Care Respir J 2004; 13 (1): 28-35
8. FitzGerald JM, Boulet LP, McIvor RA, et al. Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study. Can Respir J 2006; 13 (5): 253-259
9. Anderson HR, Ayres JG, Sturdy PM, et al. Bronchodilator treatment and deaths fromasthma: case-control study. BMJ 2005; 330 (7483): 117 doi:10.1136/bmj.38316.729907.8F (published 23 Dec 2004) (Pubitemid 40138494)
10. Spitzer WO, Suissa S, Ernst P, et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326 (8): 501-506
11. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention: NHLBI/WHO workshop report. Bethesda (MD):National Institutes of Health, National Heart, Lung and Blood Institute. Updated 2009 [online]. Available from URL: http://www.ginasthma.com. 2010 [Accessed 2010 Mar 1]
12. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337 (20): 1405-1411
13. Ind PW, Dal Negro R, Colman NC, et al. Addition of salmeterol to fluticasone propionate treatment in moderateto- severe asthma. Respir Med 2003; 97 (5): 555-562
14. Greening AP, Ind PW, Northfield M, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344 (8917): 219-224
15. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164 (8 Pt 1): 1392-1397
16. Bateman ED, Boushey HA, Bousquet J, et al. Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 2004; 170 (8): 836-844
17. Shepherd J, Rogers G, Anderson R, et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with longacting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008; 12 (19): 1-360
18. Aalbers R, Backer V, Kava TT, et al. Adjustable maintenance dosing with budesonide/formoterol compared with fixed-dose salmeterol/fluticasone in moderate to severe asthma. Curr Med Res Opin 2004; 20 (2): 225-240
19. Rabe KF, Pizzichini E, Stallberg B, et al. Budesonide/ formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129 (2): 246-256
20. Scicchitano R, Aalbers R, Ukena D, et al. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma. Curr Med Res Opin 2004; 20 (9): 1403-1418
21. O'Byrne PM, Bisgaard H, Godard PP, et al. Budesonide/ formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005; 171 (2): 129-136
22. Kuna P, Peters MJ, Manjra AI, et al. Effect of budesonide/ formoterol maintenance and reliever therapy on asthma exacerbations. Int J Clin Pract 2007; 61 (5): 725-736 (Pubitemid 46587876)
23. Rabe KF, Atienza T, Magyar P, et al. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, doubleblind study. Lancet 2006; 368 (9537): 744-753
24. Vogelmeier C, D'Urzo A, Pauwels R, et al. Budesonide/ formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 2005; 26 (5): 819-828
25. Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/ formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/ fluticasone. Respir Med 2007; 101 (12): 2437-2446
26. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244
27. NAEPP (National Asthma Education and Prevention Program). Expert Panel Report 3: Guidelines for the diagnosis and management of asthma: 2007 [online]. Available from URL: http://www.nhlbi.nih.gov/guidelines/asthma/ asthgdln.htm [Accessed 2010 May 1]
28. Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32 (3): 545-554
29. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180 (1): 59-99
30. Gibson PG, Powell H, Ducharme FM. Differential effects of maintenance long-acting beta-agonist and inhaled corticosteroid on asthma control and asthma exacerbations. J Allergy Clin Immunol 2007; 119 (2): 344-350
31. Barnes NC. The properties of inhaled corticosteroids: similarities and differences. PrimCareRespir J 2007; 16 (3): 149-154
32. Walters EH, Gibson PG, Lasserson TJ, et al. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Cochrane Database Syst Rev 2007; (1): CD001385
33. Boonsawat W, Charoenratanakul S, Pothirat C, et al. Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma. Respir Med 2003; 97 (9): 1067-1074
34. Cheung D, van Klink HC, Aalbers R. Improved lung function and symptom control with formoterol on demand in asthma. Eur Respir J 2006; 27 (3): 504-510
35. van der Woude HJ, Boorsma M, Bergqvist PB, et al. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction. Pulm Pharmacol Ther 2004; 17: 89-95
36. Palmqvist M, Arvidsson P, Beckman O, et al. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther 2001; 14: 29-34
37. Palmqvist M, Ibsen T, Mellen A, et al. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999; 160 (1): 244-249
38. van Veen A, Weller FR, Wierenga EA, et al. A comparison of salmeterol and formoterol in attenuating airway responses to short-acting beta2-agonists. Pulm Pharmacol Ther 2003; 16 (3): 153-161
39. Molimard M, Gros VL, Robinson P, et al. Prevalence and associated factors of oropharyngeal side effects in users of inhaled corticosteroids in a real-life setting. J Aerosol Med Pulm Drug Deliv 2010; 23 (2): 91-95
40. Borgstrom L, Asking L, Thorsson L. Idealhalers or realhalers? A comparison of Diskus and Turbuhaler. Int J Clin Pract 2005; 59 (12): 1488-1495